Investors sentiment decreased to 1.5 in 2019 Q2. Its down 0.01, from 1.51 in 2019Q1. It dived, as 8 investors sold XNCR shares while 32 reduced holdings. 18 funds opened positions while 42 raised stakes. 46.43 million shares or 0.38% less from 46.61 million shares in 2019Q1 were reported. Redmile Group Ltd Liability Corp accumulated 1.61M shares. Shell Asset Mgmt has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Wells Fargo And Mn stated it has 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). The New York-based Tocqueville Asset Mgmt Lp has invested 0% in Xencor, Inc. (NASDAQ:XNCR). 26,950 are owned by Deutsche Natl Bank Ag. Moreover, Rafferty Asset Mgmt Limited Liability Company has 0.02% invested in Xencor, Inc. (NASDAQ:XNCR) for 30,441 shares. Fmr Ltd Llc stated it has 8.45M shares or 0.04% of all its holdings. 443 are owned by Us State Bank De. Los Angeles Cap Equity Rech Inc, California-based fund reported 26,809 shares. Aperio Grp Limited Liability Com accumulated 0% or 3,718 shares. Dekabank Deutsche Girozentrale invested 0.01% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). First Light Asset Llc owns 2.84% invested in Xencor, Inc. (NASDAQ:XNCR) for 499,344 shares. Advisory Research reported 24,582 shares stake. Rhumbline Advisers owns 0.01% invested in Xencor, Inc. (NASDAQ:XNCR) for 82,314 shares. Legal And General Gp Public Ltd Liability Com holds 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR) for 19,421 shares.
Since June 6, 2019, it had 1 buying transaction, and 0 insider sales for $377,587 activity.
Ecor1 Capital Llc increased its stake in Xencor Ord (XNCR) by 13.46% based on its latest 2019Q2 regulatory filing with the SEC. Ecor1 Capital Llc bought 277,128 shares as the company’s stock rose 46.93% . The institutional investor held 2.34 million shares of the health care company at the end of 2019Q2, valued at $95.64M, up from 2.06M at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Xencor Ord for a number of months, seems to be bullish on the $2.24 billion market cap company. The stock increased 2.78% or $1.07 during the last trading session, reaching $39.54. About 244,647 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 23.34% since November 27, 2018 and is uptrending. It has outperformed by 23.34% the S&P500.
Ecor1 Capital Llc, which manages about $989.64M US Long portfolio, decreased its stake in Argenx Adr Rep Ord by 243,922 shares to 581,165 shares, valued at $82.28M in 2019Q2, according to the filing. It also reduced its holding in Mersana Therapeutics Ord by 907,769 shares in the quarter, leaving it with 1.39 million shares, and cut its stake in Crispr Therapeutics Ord.
More notable recent Xencor, Inc. (NASDAQ:XNCR) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) – Yahoo Finance” on October 23, 2019, also Seekingalpha.com with their article: “USANA, Xencor get lift on entry to SmallCap 600 – Seeking Alpha” published on June 24, 2019, Nasdaq.com published: “Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates – Nasdaq” on November 05, 2019. More interesting news about Xencor, Inc. (NASDAQ:XNCR) were released by: Seekingalpha.com and their article: “Xencor: Multiple Data Readouts In Second Half Of 2019 For This ‘Picks And Shovels’ Play – Seeking Alpha” published on June 30, 2019 as well as Nasdaq.com‘s news article titled: “New Strong Buy Stocks for November 14th – Nasdaq” with publication date: November 14, 2019.
Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage
Among 2 analysts covering Xencor (NASDAQ:XNCR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xencor has $5200 highest and $52 lowest target. $52’s average target is 31.51% above currents $39.54 stock price. Xencor had 6 analyst reports since June 13, 2019 according to SRatingsIntel. Canaccord Genuity maintained Xencor, Inc. (NASDAQ:XNCR) on Thursday, August 8 with “Buy” rating. Mizuho maintained the shares of XNCR in report on Sunday, October 20 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.